April 29, 2015
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
The purpose of the study was to validate logistic regression models, termed Mi-Prostate Score (MiPS), that incorporate serum prostate-specific antigen (PSA; or the multivariate Prostate Cancer Prevention Trial risk calculator version 1.0 [PCPTrc]) and urine T2:ERG and PCA3 scores for predicting PCa and high-grade PCa on biopsy. The conclusions are that incorporation of two prostate cancer(PCa)-specific biomarker s(TMPRSS2:ERG and PCA3) measured in the urine improved on serum prostate-specific antigen (or a multivariate risk calculator) for predicting the presence of PCa and high-grade PCa on biopsy. A combined test, MyProstate Score, uses models validated in this study and is clinically available to provide individualized risk estimates.